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Abstract
Background: Circadian genes continue to gain attention as important transcriptional regulators with the potential to 
influence a variety of biological pathways, including many cancer-related processes. The core circadian gene 
cryptochrome 2 (CRY2) is essential for proper circadian timing, and is a key component of the negative arm of the 
circadian feedback loop. As such, aberrant expression of CRY2 may influence carcinogenic processes and thereby 
impact cancer susceptibility.
Methods: We silenced CRY2 in breast cancer cell lines (MCF-7) using small-interfering oligos (siRNA) and measured the 
impact of CRY2 knockdown on a number of cancer-relevant parameters. Cell cycle distribution, cell viability, and 
apoptotic response were measured in CRY2 knockdown (CRY2-) and normal (CRY2+) cell populations using flow 
cytometry in cells with and without exposure to a mutagen challenge. DNA damage accumulation was measured 
using the single cell gel electrophoresis (comet) assay, and damage was quantified using the Olive tail moment, which 
considers the amount and distance of DNA migration away from the nucleus, indicative of DNA strand breaks. 
Expression changes in cancer-relevant transcripts were measured by whole genome microarray. The Student's t-test 
was used for statistical comparisons, and P-values obtained from the microarray were adjusted for multiple 
comparisons using the false discovery rate correction, in order to obtain an adjusted Q-value for each observation.
Results: The comet assay results indicated that upon exposure to the same dose of chemical mutagen, CRY2- cells 
accumulate significantly more unrepaired DNA damage than CRY2+ cells (P = 0.040), suggesting that CRY2 may be 
important for DNA repair. In addition, a number of transcripts with relevance for DNA damage repair displayed altered 
expression following CRY2 silencing. These included BCCIP (Q = 0.002), BCL2 (Q = 0.049), CCND1 (Q = 0.009), CDKN1A (Q 
< 0.001), GADD45A (Q = 0.002), HERC5 (Q < 0.001), MCM5 (Q = 0.042), PPP1R15A (Q < 0.001), SUMO1 (Q < 0.001), and 
UBA1 (Q = 0.023). However, no significant influence of CRY2 knockdown on cell cycle distributions, cell cycle 
checkpoints in response to mutagen challenge, or apoptotic response was detected.
Conclusions: In total, these data suggest a limited, but potentially important role for CRY2 in the regulation of DNA 
damage repair and the maintenance of genomic stability. Future investigations may focus on identifying the 
mechanisms by which CRY2 may regulate the expression of transcripts with known relevance for carcinogenesis.
Background
Although our understanding of the molecular basis for
the circadian rhythm is continually evolving, the current
model involves a complex interplay between environ-
mental and endogenous factors, which include a core set
of circadian genes [1]. Transcriptional and post-tran-
scriptional interactions among these gene products
results in an autoregulatory feedback system, which
allows for predictable cycling of the core circadian ele-
ments [2-4]. In addition, many of the circadian genes
operate as transcriptional regulators for transcripts out-
side of the circadian system, and recent evidence indi-
cates that as many as 10% of all mammalian genes may be
regulated to some degree by the circadian oscillatory
mechanism [5-7]. As a result, disturbance of the circadian
system, either through environmental exposures, or
through genetic alterations in the key circadian genes,
may have important implications for a variety of biologi-
cal pathways.
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One such core circadian gene, CRY2, operates in the
negative arm of the circadian feedback loop as a tran-
scriptional repressor [8]. CRY2 has also been shown to be
involved in cancer-relevant pathways including DNA
damage checkpoint control [9] and regulation of genes
important for cell cycle progression [10,11]. However,
Cry1-/-, Cry2-/- transgenic mice do not display a cancer-
prone phenotype in response to ionizing radiation expo-
sure [10]. Here, we report findings from in vitro loss-of-
function investigations into the phenotypic effects of
CRY2  knockdown on cell cycle, apoptosis, and DNA
damage response to mutagen challenge in a breast cancer
cell line. We also investigate a whole genome expression
array to interrogate the impact of CRY2 silencing on the
expression of genes relevant to these pathways.
Methods
Cell culture and treatments
Human breast adenocarcinoma cells (MCF-7; American
Type Culture Collection, Manassas, VA) were maintained
in Dulbecco's modified Eagle medium (Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum
(Invitrogen), 0.01 mg/ml bovine insulin, and 1% penicil-
lin/streptomycin (Sigma-Aldrich, St. Louis, MO). siRNA
oligos were designed and manufactured by Integrated
DNA Technologies (IDT, Coralville, IA), targeting either
CRY2 (Sense: 5'-UGCUUCAUUCGUUCAAU-
GUUAAGCCGG-3' Antisense: 5'-GGCUUAACAUU-
GAACGAAUGAAGCA-3') or a scrambled sequence
negative control siRNA (Sense: 5'-CUUCCUCUCUUU-
CUCUCCCUUGUGA-3', Antisense: 5'-UCACAAGG-
GAGAGAAAGAGGGAAGGA-3'). Each oligo was
complexed and reverse transfected using Lipofectamine
RNAiMax transfection reagent (Invitrogen) at a final
oligo concentration of 10 nM. Cells were either harvested
48 hours after transfection, to assay for knockdown effi-
ciency by qPCR, or incubated with either PBS (neg. con-
trol) or 0.03% (v/v) methyl methanesulfonate (MMS,
chemical mutagen) for use in subsequent assays.
RNA isolation and quantitation
RNA samples were isolated from harvested cells using the
RNA Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer's instructions for mammalian cells, includ-
ing on-column DNA digestion. Gene expression was
quantified by two-step quantitative RT-PCR, beginning
with first-strand cDNA synthesis using the AffinityScript
cDNA kit (Stratagene, La Jolla, CA) with oligo-dT prim-
ers, followed by quantitative real-time PCR using the
Power SYBR Green PCR master mix (Applied BioSys-
tems, Foster City, CA). The primers used for CRY2 ampli-
fication were: (L: ACCGGGGACTCTGTCTACTG, R:
GCCTGCACTGCTCATGCT). RNA quantity was nor-
malized using HPRT1 content, and CRY2 silencing was
quantified prior to each treatment according to the 2-ΔΔCt
method. In each case, CRY2 was reduced to less than 20%
of the levels seen in the mock siRNA-treated negative
control (i.e. 5-fold downregulation).
Whole genome expression microarray and pathway-based 
expression analysis
A whole genome expression microarray (Agilent, Inc 44k
chip, performed by MoGene, LC, St Louis, MO) was used
to interrogate gene expression in cells with normal and
reduced  CRY2. The results of these experiments have
been uploaded to the Gene Expression Omnibus (GEO)
database, and can be accessed by referencing accession
#GSE14617. In order to determine whether genes
involved in cell cycle regulation and DNA damage
response were influenced by CRY2 knockdown, we ana-
lyzed the microarray expression data for genes in SABio-
science's "Human Cell Cycle" and "Human DNA Damage
Signaling Pathway" arrays (catalog numbers PAHS-020
and PAHS-029, respectively). All fold changes are the
result of two biological replicates of the microarray
experiment, and all observations with low intensity (<50)
in both CRY2 normal and CRY2 knockdown populations
have been discarded. Significantly altered genes were
confirmed by qPCR, and the primers used for these reac-
tions can be found in Additional file 1.
Cell cycle, cell viability, and apoptosis assays
Cells with normal and reduced CRY2 levels were stained
with propidium iodide (PI) and analyzed by flow cytome-
try using a fluorescence-activated cell sorter (FACS) flow
cytometer (Becton Dickinson, San Jose, CA). Prior to
analysis, cells were treated with either PBS or MMS for 1
hour, followed by duplicate washes and 24 hour incuba-
tion in normal growth medium. Cell populations from
each treatment group were analyzed using the FlowJo
flow cytometry analysis software (Tree Star, Inc., Ash-
land, OR), and cell phases were determined using the
Watson pragmatic algorithm [12]. Cells from each of the
four treatment groups (CRY2 +/-, MMS +/-) were also
assayed for viability and apoptosis using the Vybrant
Apoptosis Assay Kit #2 (Invitrogen). Briefly, cells were
stained with PI and Annexin V according to the manufac-
turer's protocol, and scored as live, dead, apoptotic or
ambiguous by flow cytometry. All results are based on the
average of triplicate experiments. Raw flow cytometry
images from each analysis are available in Additional
file 2.
DNA Damage Assay
DNA damage accumulation was measured by alkaline
single-cell gel electrophoresis (i.e. the comet assay). Cells
with normal and reduced CRY2  levels were incubated
with MMS for one hour, followed by two PBS washes andHoffman et al. BMC Cancer 2010, 10:110
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3 hours of recovery time. Cells were then fixed onto slides
with low-melting agarose, lysed, and treated with pH>14
solution at 4°C to denature the DNA. Slides were then
subjected to electrophoresis to allow damaged DNA to
migrate away from the nucleus, and then stained with
ethidium bromide. In order to reduce the possibility of
observer bias, the prepared slides were then given to a
second person who scrambled them and assigned his
own arbitrary numeric label to each slide before return-
ing them for scoring. As such, the person responsible for
generating the data was unaware of the treatment status
for each slide. 50 cells from each treatment group were
analyzed by fluorescence microscopy using the Komet 5
comet assay analysis software. DNA damage was quanti-
fied by the software using the mean Olive tail moment
calculation for each cell, as previously described [13].
Once the scoring was complete, the data were sent back
to the second person who replaced the numeric label with
the treatment identity. All results are from duplicate
experiments performed on 50 cells each.
Statistical Analysis
All statistical analyses were performed using the SAS sta-
tistical software (SAS Institute, Cary, NC), unless other-
wise noted. CRY2 knockdown was assessed using the 2-
ΔΔCt method with RNA content normalized to the house-
keeping gene HPRT1. Differences in cell cycle distribu-
tion were investigated by determining the percentage of
cells in each phase for each treatment group. The CRY2
normal population was then compared to the CRY2
reduced population with and without mutagen challenge
using the Student's t-test. Similar comparisons were
made for cell viability and apoptotic response, comparing
CRY2 normal and CRY2 reduced populations using the t-
test. For the comet assay, comparisons were for the mean
Olive tail moment in cells with reduced and normal
CRY2, and again, the t-test was used. Due to the large
number of observations present in the microarray, P-val-
ues were adjusted for multiple comparisons using the
false discovery rate correction, as previously described
[14], in order to obtain an adjusted Q-value for each
observation.
Results
Silencing of CRY2 does not influence cell cycle distribution, 
cell cycle checkpoints, cell death, or apoptosis in response 
to mutagen challenge
Cell cycle distributions in mock-treated or mutagen chal-
lenged cells were measured in populations with normal
(CRY2+) and reduced CRY2 levels (CRY2-). In both treat-
ment groups, similar distributions were observed for
CRY2+ and CRY2- cell populations, indicating that
reduction of CRY2 alone is not sufficient to significantly
impact cell cycle regulation. The cell phase distributions
in mock treated cells were: CRY2+: G1, 42.3%, S, 48.5%,
G2/M, 9.2%; CRY2-: G1, 42.7%, S, 46.6%, G2/M, 10.8%
(Figure 1). In addition, a similar magnitude of G1 delay
was observed in both the CRY2+ and CRY2- populations
following mutagen challenge, suggesting that CRY2 does
not significantly influence DNA damage-induced cell
cycle checkpoint control. Cell cycle distributions in
mutagen treated cells were: CRY2+: G1, 58.3%, S, 34.3%,
G2/M, 7.4%; CRY2-: G1, 58.1%, S, 33.7%, G2/M, 8.2%.
Flow cytometric analyses of necrosis and apoptosis in
mock and mutagen treated cells also revealed no signifi-
cant differences in CRY2+ and CRY2- cell populations.
Both populations had similarly low percentages of
necrotic and apoptotic cells in the mock treated popula-
tions:  CRY2+: necrotic 3.5%, apoptotic, 1.5%; CRY2-:
necrotic, 3.8%, apoptotic 1.2% (Figure 2). The percentage
of necrotic and apoptotic cells in both these populations
increased by similar margins following mutagen chal-
lenge:  CRY2+: necrotic 12.8%, apoptotic, 9.1%; CRY2-:
necrotic, 14.8%, apoptotic 7.5%. No comparisons, either
in the percentage of necrotic or apoptotic cells, or in the
magnitude of the response following mutagen challenge,
were statistically significant.
CRY2 knockdown results in increased accumulation of 
mutagen-induced DNA damage
The single cell gel electrophoresis (comet) assay was used
to evaluate the extent of DNA damage following mutagen
challenge in CRY2+ and CRY-populations. DNA damage
was quantified using the Olive tail moment measure,
which incorporates the distance of DNA migration from
the nucleus, as well as the percentage of total DNA which
has migrated away from the nuclear core, indicating that
it has been relaxed or broken. The mean Olive tail
Figure 1 Cell cycle distributions in CRY2- and CRY2+ cells in mock 
and mutagen treated cell populations. Both in the absence and 
presence of mutagen, cells with reduced CRY2 had a similar cell cycle 
distribution as cells with normal CRY2 levels, suggesting no direct im-
pact of CRY2 on cell cycle progression or cell cycle checkpoints in re-
sponse to DNA damage. All results are based on the average of 
triplicate experiments, and error bars are for SEM.Hoffman et al. BMC Cancer 2010, 10:110
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moment in CRY2- cells was significantly higher than that
in CRY2+ cells (P = 0.04), indicating that the same levels
of mutagen exposure result in greater DNA damage in
cells with reduced CRY2  (Figure 3). This is especially
notable given that CRY2- cells do not exhibit decreased
survival or increased apoptosis, suggesting that they sur-
vive equally well despite the increased level of DNA dam-
age; a phenotype which could lead to tumor promotion.
CRY2 knockdown results in expression changes in genes in 
the DNA damage response and cell cycle regulatory 
pathways
A whole genome expression microarray was performed
using RNA isolated from CRY2+ and CRY2- cell popula-
tions. Using the genes in the SABioscience cell cycle and
DNA damage response arrays, we identified 10 genes in
these pathways which displayed significantly altered
expression following CRY2 knockdown (Q-value < 0.05).
Expression of each of these genes was also determined by
qPCR for each cell treatment in order to confirm the
array results. All genes were altered in the same direction
when measured by array or qPCR, and all fold changes
were of similar magnitude, with the exception of SUMO1,
which was two-fold upregulated in the array, but only
1.32 upregulated when measured by qPCR (Table 1).
Among the significantly altered gene set were cyclin
dependent kinase inhibitor p21 (CDKN1A; fold change =
1.7, Q < 0.001) along with its interacting protein (BCCIP;
fold change = 2.3, Q = 0.002). Perhaps most interesting,
however, was the induction of cyclin D1 (CCND1; fold
change = 1.5, Q = 0.009) in cells with reduced CRY2.
CCND1  is a firmly established oncogene that is often
overexpressed in primary breast cancers [15], and while
aberrant overexpression of CCND1 is often due to gene
a m p l i f i c a t i o n ,  u p  t o  5 0 %  o f  b r e a s t  c a n c e r s  d i s p l a y
increases in CCND1, many of which cannot be explained
by copy number variations, indicating that alternative
mechanisms such as transcriptional dysregulation must
be involved [16].
Discussion
CRY2, in conjunction with CRY1 and the period genes,
(PER1, PER2, and PER3) operates on the negative arm of
the circadian system and is essential for maintaining
proper circadian rhythm [17]. However, due to the com-
plex nature of circadian gene interactions, which include
pre- and post-transcriptional regulation, it remains diffi-
cult to determine the direct phenotypic impact of a single
gene, especially in light of the potential for overlapping
functions and compensatory mechanisms among the
core circadian proteins. Nevertheless, the observation
that cells with reduced CRY2 accumulate greater DNA
damage is consist with the general understanding that
circadian genes may directly influence organismal sus-
ceptibility to genotoxic stress [18].
The finding that CCND1  is induced following CRY2
knockdown, while not proof of direct inhibition of
CCND1 by CRY2, does provide the intriguing possibility
that the aberrant overexpression of CCND1 observed in
several cancer types could be, in part, the result of circa-
dian-mediated transcriptional dysregulation. Evidence
for this association was provided by an earlier study
which showed that enforced expression of PER2 resulted
Figure 2 Cell death and apoptosis in CRY2+ and CRY2- cell popu-
lations. No differences were observed in CRY2 knockdown cells in 
terms of necrosis or apoptosis, with or without mutagen exposure. All 
results are based on the average of triplicate experiments, and error 
bars are for SEM.
Figure 3 Comet assay results for cells with reduced and normal 
CRY2. DNA damage was measured by the Olive tail moment, which 
considers the amount and distance of DNA migration away from the 
nucleus, indicative of DNA strand breaks. Higher values correspond to 
increased damage. Upon exposure to the same concentration of mu-
tagen, CRY2- cells accumulated significantly more DNA damage com-
pared to normal cells (P = 0.040). Comet assay results are from 
duplicate experiments performed on 50 cells each. All data are aggre-
gated (i.e. 100 cells per treatment), and error bars are for SEM.Hoffman et al. BMC Cancer 2010, 10:110
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in a 56% reduction in CCND1 levels in vitro [19]. Interest-
ingly, in addition to the positive regulator of cell cycle
progression, CCND1, a crucial cyclin-dependent kinase
inhibitor,  CDKN1A  (also known as P21), was also
induced after CRY2 knockdown. This finding is consis-
tent with a recent report demonstrating that clock-defi-
cient mice have increased levels of p21, resulting in
decreased cellular proliferation rates [20]. That both
CCND1  and  CDKN1A, which influence cell cycle pro-
gression in opposite directions, were each upregulated
after CRY2 knockdown provides a potential explanation
for the lack of observable phenotypic impact of CRY2
silencing on cell cycle distributions. Given the impor-
tance of these cell cycle regulators in a variety of cancer
types, additional exploration into the nature of these
associations is warranted.
Despite evidence that cryptochromes may be involved
in cancer-associated processes [11], two in vivo studies
did not find a cancer-prone phenotype in double mutant
mice lacking both crytpochrome genes (i.e. Cry1-/-Cry2-
/-). For example, Cry1-/-Cry2-/- mice did not have poorer
survival rates than wild type (WT) mice following expo-
sure to ionizing radiation [10]. In addition, fibroblasts
derived from these mice did not have deficient DNA
damage capacities compared to those derived from wild
type mice, and cell cycle checkpoints were similarly unaf-
fected. Another study of Cry1-/-Cry2-/- also showed that
while these mice were significantly smaller than their WT
counterparts, they did not have any obvious malignan-
cies, and they remained reproductively fit [21]. Interest-
ingly, in mice which are predisposed to cancer due to a
mutation in p53, addition of the Cry mutation results in
sensitization of p53 mutant cells to apoptosis and thus
decreased cancer risk and increased survival [22]. In
addition, there is a strong circadian rhythm in nucleotide
excision repair activity in the mouse brain, caused at least
Table 1: Cell cycle and DNA damage repair genes with altered expression following CRY2 silencing.
Gene RefSeq Description Array Fold 
Change
Q-Value qPCR Fold 
Change
BCCIP NM_078469 BRCA2 and 
CDKN1A 
interacting 
protein
2.33 0.0021 1.57
BCL2 NM_000633 B-cell CLL/
lymphoma 2
-1.47 0.0487 -1.50
CCND1 NM_053056 Cyclin D1 1.51 0.0087 1.33
CDKN1A NM_000389 Cyclin-dependent 
kinase inhibitor 
1A (p21, Cip1)
1.71 0.0001 1.98
GADD45A NM_001924 Growth arrest and 
DNA-damage-
inducible, alpha
1.92 0.0015 2.16
HERC5 NM_016323 Hect domain and 
RLD 5
3.93 0.0000 2.28
MCM5 NM_006739 Minichromosome 
maintenance 
complex 
component 5
-1.58 0.0415 -1.46
PPP1R15A NM_014330 Protein 
phosphatase 1, 
regulatory 
(inhibitor) subunit 
15A
2.55 0.0004 2.45
SUMO1 NM_001005781 SMT3 suppressor 
of mif two 3 
homolog 1 (S. 
cerevisiae)
2.00 0.0002 1.32
UBA1 NM_003334 Ubiquitin-like 
modifier 
activating 
enzyme 1
1.58 0.0232 1.43Hoffman et al. BMC Cancer 2010, 10:110
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partly by circadian regulation of xeroderma pigmento-
sum A (XPA) [23]. Cry negatively regulates this activity,
and fibroblasts from Cry1-/-Cry2-/- mice exhibit 3-fold
induction of XPA protein. It should be noted, however,
that each of these studies employed double mutant mice,
and are thus not necessarily reflective of the condition
which may exist in the absence of Cry2 only. In fact, a
behavioral and molecular study of the effect of crypto-
chromes on light entrainment and circadian regulation
showed very different phenotypes for Cry1-/-Cry2-/-
mice compared to mice lacking Cry1 only [24], and an
earlier study of Cry-/- mice suggested that reductions in
either cryptochrome alone have effects which are directly
opposed to one another [8]. To the best of our knowledge,
no study has yet explored the response of Cry2-/- only to
mutagen challenge, or the effect of induced degradation
of CRY2 on DNA repair. It should also be noted that our
data are generated using cells with wild-type p53. Thus,
future studies may wish to investigate the effect of CRY2
knockdown in mutant p53 cells, especially in light of the
recent evidence suggesting differential effects of Cry
mutations against the p53 mutant background, as out-
lined above.
While changes were detected in DNA damage accumu-
lation following CRY2 knockdown, no differences were
observed in other cancer-related pathways. However, pre-
vious studies have shown that induction of the DNA
damage response pathway is an important early event in
determining whether precursor lesions will develop into
malignancies [25], and those authors suggest that muta-
tions which disrupt the DNA damage response may allow
tumor progression. In another study, Gorgoulis et al.
demonstrate that a DNA damage response is present in
precancerous lesions, also suggesting that disruption of
this pathway could be an important determinant of pro-
gression to carcinoma [26]. One interesting aspect of our
phenotypic assays was the increase in DNA damage
observed in CRY2- cell populations in the absence of
decreased survival or increased apoptosis. If in fact
reduced CRY2 results in increased DNA damage without
triggering increases in cell death or apoptosis, this could
potentially lead to cancer, as damaged cells could survive
and be allowed to proliferate. As such, this phenotype
warrants further investigation.
Conclusion
In summary, these data suggest a limited, but potentially
important role for CRY2 in maintaining genomic stability.
Future investigations may wish to focus on the transcrip-
tional influence of CRY2 on oncogenic CCND1, and the
relationship with CDKN1A,  a s  t h e s e  f i n d i n g s  h a v e  t h e
potential for broad impact on a number of cancer types.
In addition, given the evidence that response to cancer
therapy may be influenced by circadian cycling
[18,27,28], and the fact that CRY2  may influence the
accumulation of DNA damage, future investigations into
the effects of CRY2 on response to treatment are also
warranted.
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